Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

摘要: Purpose The antiepidermal growth factor receptor (EGFR) antibody cetuximab shows activity in multiple epithelial tumor types; however, responses are seen only a subset of patients. This study was conducted to identify markers that associated with disease control patients treated cetuximab. Patients and Methods One hundred ten metastatic colorectal cancer were enrolled onto monotherapy trial. Transcriptional profiling on RNA from mandatory pretreatment biopsies genes whose expression correlates best clinical responses. EGFR K-ras mutation analyses gene copy number performed DNA biopsies. Results Gene profiles showed tumors express high levels the ligands epiregulin amphiregulin more likely have (EREG, P .000015; AREG, .000025). Additionally, do not mutations significantly higher rate than (P .0003). Furthermore, EREG or AREG also longer progression-free survival (PFS) low (EREG: .0002, hazard ratio [HR] 0.47, median PFS, 103.5 v 57 days, respectively; AREG: .0001, HR 0.44, 115.5 respectively). Conclusion wild-type treatment. identified could be developed further select for therapy. J Clin Oncol 25:3230-3237. © 2007 by American Society Clinical Oncology